Coherus Bio (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -237,892 | -291,754 | -287,100 | 132,244 | 89,833 |
| Depreciation Amortization | 3,791 | 3,699 | 3,454 | 2,888 | 3,259 |
| Accounts receivable | -150,683 | 13,052 | 34,062 | -15,218 | -141,992 |
| Accounts payable and accrued liabilities | 23,760 | -4,548 | 874 | -9,820 | 9,893 |
| Other Working Capital | -34,350 | -76,754 | 44,567 | -34,651 | -112,534 |
| Other Operating Activity | 220,490 | 115,181 | 166,711 | 78,702 | 179,896 |
| Operating Cash Flow | $-174,884 | $-241,124 | $-37,432 | $154,145 | $28,355 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -286 | -2,039 | -1,289 | -7,231 | -1,822 |
| Net Acquisitions | 7,842 | N/A | N/A | 175 | N/A |
| Purchase Of Investment | -19,507 | -127,382 | -182,485 | -273,845 | -20,235 |
| Sale Of Investment | 157,642 | 0 | 181,364 | 274,000 | 20,400 |
| Other Investing Activity | -1,051 | -37,429 | -136,000 | -7,500 | -11,075 |
| Investing Cash Flow | $144,640 | $-166,850 | $-138,410 | $-14,401 | $-12,732 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 240,679 | N/A | 222,156 | N/A |
| Debt Repayment | N/A | -190,750 | N/A | -18,170 | N/A |
| Common Stock Issued | 74,221 | 9,369 | 54,304 | 17,428 | 13,711 |
| Common Stock Repurchased | N/A | N/A | N/A | 3,801 | 3,519 |
| Other Financing Activity | -4,621 | -4,972 | -2,425 | -1,269 | 72,140 |
| Financing Cash Flow | $69,600 | $54,326 | $51,879 | $223,946 | $89,370 |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | -276 |
| Beginning Cash Position | 63,987 | 417,635 | 541,598 | 177,908 | 73,191 |
| End Cash Position | 103,343 | 63,987 | 417,635 | 541,598 | 177,908 |
| Net Cash Flow | $39,356 | $-353,648 | $-123,963 | $363,690 | $104,717 |
| Free Cash Flow | |||||
| Operating Cash Flow | -174,884 | -241,124 | -37,432 | 154,145 | 28,355 |
| Capital Expenditure | -286 | -2,039 | -1,289 | -7,231 | -1,822 |
| Free Cash Flow | -175,170 | -243,163 | -38,721 | 146,914 | 26,533 |